发明名称 Phosphorylcholine conjugates and corresponding antibodies
摘要 IgG and IgM autoantibody levels against phosphorylcholine in subjects with hypertension (diastolic pressure >95 mmHg) were determined at baseline in order to determine the importance of antibodies for the development of atherosclerosis. The results show that increases in intima 5 media thickness (IMT) at a follow-up four years after baseline were significantly less prevalent in subjects having high autoantiboides particularly high IgM autoantibodies, to phosphorylcholine. The presence or absence of autoantibodies, particularly IgM autoantibodies, against phosphoryicholine is thus related to an increased or decreased risk of developing ischemic cardiovascular diseases. A method to determining antibodies, particularly IgM [0 antibodies, toward phosphorylcholine is proposed in this invention to identify subjects at risk of developing ischemic cardiovascular diseases. Animal experiments show that medium to high levels of antibodies, particularly IgM antibodies, can be detected in plasma after active immunization with a keyhole limpet hemocyanin (KLH)-phosphorylcholine conjugate. A pharmaceutical composition comprising a phosphorylcholine conjugate (active immunization) or [5 an antibody preparation, for example a monoclonal antibody, with specificity to a phosphorylcholine conjugate (passive immunization) is proposed and the use of these compositions as active or passive immunogen is the treatment or prevention of atheroscleoris.
申请公布号 AU2011202334(B2) 申请公布日期 2012.12.06
申请号 AU20110202334 申请日期 2011.05.19
申请人 ATHERA BIOTECHNOLOGIES AB 发明人 DE FAIRE, ULF;FROSTEGARD, JOHAN
分类号 C07K16/44;A61K47/48;C07K16/18;G01N33/68;G01N33/92 主分类号 C07K16/44
代理机构 代理人
主权项
地址
您可能感兴趣的专利